JP2020518591A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518591A5
JP2020518591A5 JP2019559744A JP2019559744A JP2020518591A5 JP 2020518591 A5 JP2020518591 A5 JP 2020518591A5 JP 2019559744 A JP2019559744 A JP 2019559744A JP 2019559744 A JP2019559744 A JP 2019559744A JP 2020518591 A5 JP2020518591 A5 JP 2020518591A5
Authority
JP
Japan
Prior art keywords
cells
less
administration
cell therapy
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019559744A
Other languages
English (en)
Japanese (ja)
Other versions
JP7299841B2 (ja
JP2020518591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030545 external-priority patent/WO2018204427A1/en
Publication of JP2020518591A publication Critical patent/JP2020518591A/ja
Publication of JP2020518591A5 publication Critical patent/JP2020518591A5/ja
Priority to JP2023098900A priority Critical patent/JP7830386B2/ja
Application granted granted Critical
Publication of JP7299841B2 publication Critical patent/JP7299841B2/ja
Priority to JP2026033824A priority patent/JP2026083262A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019559744A 2017-05-01 2018-05-01 細胞療法と免疫調節化合物の併用 Active JP7299841B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023098900A JP7830386B2 (ja) 2017-05-01 2023-06-16 細胞療法と免疫調節化合物の併用
JP2026033824A JP2026083262A (ja) 2017-05-01 2026-03-04 細胞療法と免疫調節化合物の併用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762492947P 2017-05-01 2017-05-01
US62/492,947 2017-05-01
US201762538670P 2017-07-29 2017-07-29
US62/538,670 2017-07-29
US201762549390P 2017-08-23 2017-08-23
US62/549,390 2017-08-23
US201762580433P 2017-11-01 2017-11-01
US62/580,433 2017-11-01
US201762596753P 2017-12-08 2017-12-08
US62/596,753 2017-12-08
PCT/US2018/030545 WO2018204427A1 (en) 2017-05-01 2018-05-01 Combination of a cell therapy and an immunomodulatory compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023098900A Division JP7830386B2 (ja) 2017-05-01 2023-06-16 細胞療法と免疫調節化合物の併用

Publications (3)

Publication Number Publication Date
JP2020518591A JP2020518591A (ja) 2020-06-25
JP2020518591A5 true JP2020518591A5 (cg-RX-API-DMAC10.html) 2021-06-17
JP7299841B2 JP7299841B2 (ja) 2023-06-28

Family

ID=62563245

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019559744A Active JP7299841B2 (ja) 2017-05-01 2018-05-01 細胞療法と免疫調節化合物の併用
JP2023098900A Active JP7830386B2 (ja) 2017-05-01 2023-06-16 細胞療法と免疫調節化合物の併用
JP2026033824A Pending JP2026083262A (ja) 2017-05-01 2026-03-04 細胞療法と免疫調節化合物の併用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023098900A Active JP7830386B2 (ja) 2017-05-01 2023-06-16 細胞療法と免疫調節化合物の併用
JP2026033824A Pending JP2026083262A (ja) 2017-05-01 2026-03-04 細胞療法と免疫調節化合物の併用

Country Status (19)

Country Link
US (1) US20200078404A1 (cg-RX-API-DMAC10.html)
EP (2) EP3618842B1 (cg-RX-API-DMAC10.html)
JP (3) JP7299841B2 (cg-RX-API-DMAC10.html)
KR (2) KR102707505B1 (cg-RX-API-DMAC10.html)
CN (2) CN111182909A (cg-RX-API-DMAC10.html)
AU (2) AU2018263887B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019022893A2 (cg-RX-API-DMAC10.html)
CA (1) CA3061945A1 (cg-RX-API-DMAC10.html)
DK (1) DK3618842T3 (cg-RX-API-DMAC10.html)
ES (1) ES2967467T3 (cg-RX-API-DMAC10.html)
FI (1) FI3618842T3 (cg-RX-API-DMAC10.html)
IL (2) IL270250B2 (cg-RX-API-DMAC10.html)
MA (1) MA51871A (cg-RX-API-DMAC10.html)
MX (1) MX2019012975A (cg-RX-API-DMAC10.html)
PH (1) PH12019502470A1 (cg-RX-API-DMAC10.html)
PL (1) PL3618842T3 (cg-RX-API-DMAC10.html)
PT (1) PT3618842T (cg-RX-API-DMAC10.html)
SG (1) SG11201910143TA (cg-RX-API-DMAC10.html)
WO (1) WO2018204427A1 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
WO2018132518A1 (en) 2017-01-10 2018-07-19 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US12049667B2 (en) 2017-05-26 2024-07-30 Abvitro Llc High-throughput polynucleotide library sequencing and transcriptome analysis
CA3075716A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US11066475B2 (en) * 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN113573719A (zh) * 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
CN113747896A (zh) * 2019-04-22 2021-12-03 斯塔顿治疗公司 来那度胺和其他免疫调节剂的连续递送
WO2020220027A1 (en) * 2019-04-25 2020-10-29 Purdue Research Foundation Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
EP4054623A1 (en) * 2019-11-07 2022-09-14 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione
JP7879804B2 (ja) * 2019-12-06 2026-06-24 フェイト セラピューティクス,インコーポレイテッド 小化合物を使用するiPSC由来エフェクター免疫細胞の増強
WO2021113776A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN115003818A (zh) * 2020-01-22 2022-09-02 科济生物医药(上海)有限公司 病毒载体转导细胞的方法
JP2023519099A (ja) * 2020-02-12 2023-05-10 ジュノー セラピューティクス インコーポレイテッド Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用
US12655229B2 (en) * 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
IL297147B1 (en) * 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
CA3181399A1 (en) * 2020-04-28 2021-11-04 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
WO2022137181A1 (en) * 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
CN113024671B (zh) * 2020-12-31 2022-05-24 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
IL307257A (en) * 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
WO2023009700A2 (en) * 2021-07-29 2023-02-02 Takeda Pharmaceutical Company Limited Car-expressing immune cells that specifically target mesothelin and uses thereof
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
TR200101500T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2000055134A1 (en) 1999-03-18 2000-09-21 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
SG10202109752XA (en) * 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3166968B1 (en) 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
JP2017528433A (ja) * 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
AU2015292744C1 (en) * 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
BR112017005766B1 (pt) 2014-09-22 2022-10-25 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linha de produção para a fabricação de produtos, de forma sucessiva e método para a produção de produtos individuais, de forma sucessiva, em ciclo contínuo, em uma linha de produção
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
US20180140602A1 (en) * 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
EP3770168A1 (en) * 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
SI3313818T1 (sl) * 2015-06-26 2024-03-29 Celgene Corporation Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017058754A1 (en) * 2015-09-28 2017-04-06 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
EP3525803B1 (en) * 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CN109983027A (zh) * 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体
CA3042049A1 (en) * 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
MA46716A (fr) * 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
JP2019536460A (ja) * 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Car−t細胞の調節方法
US20200078400A1 (en) * 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
US11590167B2 (en) * 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
CN109752300A (zh) 2019-01-02 2019-05-14 五邑大学 一种涂料生产安全智能巡检机器人、系统及方法

Similar Documents

Publication Publication Date Title
Cohen et al. How to train your T cells: overcoming immune dysfunction in multiple myeloma
AU2020200315B2 (en) Use of cart19 to deplete normal b cells to induce tolerance
JP2022512971A5 (cg-RX-API-DMAC10.html)
CN113713095B (zh) 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体
Kohrt et al. Targeting CD137 enhances the efficacy of cetuximab
AU2020374947C1 (en) Anti-CD47 and anti-CD20 based treatment of blood cancer
JP2019532997A5 (cg-RX-API-DMAC10.html)
JP2019536460A5 (cg-RX-API-DMAC10.html)
TWI914401B (zh) 治療癌症之方法、治療劑及用途
IL305621A (en) Methods for training patients for T-cell therapy
JP2022159476A (ja) 抗gitr抗体およびその使用
JP2020511462A5 (cg-RX-API-DMAC10.html)
WO2019144126A1 (en) Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
JP2022537700A5 (cg-RX-API-DMAC10.html)
JP2020519579A (ja) Lrrc33阻害剤およびその使用
WO2021084063A1 (en) Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
Clerico et al. Non-Hodgkin lymphoma treated with anti-CD20 antibody-based immunochemotherapy
Liu et al. Targeting dendritic cells with a PD-L1 based bispecific antibody rejuvenates specific anti-tumor T cells
HK1259030A1 (zh) 具有抗趋除特性的修饰的天然杀伤细胞及其用途
Klausz et al. Potent Targeting of the Glycoantigen CD75s on Myeloma by the Tetravalent, Fc-Engineered Antibody ‘EBU-141 Tetra’
Sibéril Tight Interplay Between Therapeutic Monoclonal
CN118043067A (zh) 嵌合tim4受体及其用途
RU2019138707A (ru) Сочетание клеточной терапии и иммуномодуляторного соединения
Kato Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future
US20180273897A1 (en) Modified t-cells having anti-fugetactic properties and uses thereof